In This Article:
Editas Medicine ( (EDIT) ) has provided an announcement.
Stay Ahead of the Market:
-
Discover outperforming stocks and invest smarter with Top Smart Score Stocks
-
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, aiming to advance its gene editing technologies targeting hematopoietic stem cells and liver cells. The company plans to declare two in vivo development candidates and expand its therapeutic possibilities, positioning itself as a leader in the in vivo gene editing field with a strong financial runway into 2027.
More about Editas Medicine
Editas Medicine is a pioneering gene editing company focused on translating the power and potential of CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into transformative in vivo medicines for serious diseases globally. The company aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines and holds exclusive licenses for Cas12a and Cas9 patent estates for human medicines.
YTD Price Performance: -3.82%
Average Trading Volume: 2,643,952
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $104M
For an in-depth examination of EDIT stock, go to TipRanks’ Stock Analysis page.